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Background: Obesity is increasingly associated with COPD, but little is known about the 
prevalence of ectopic fat accumulation in COPD and whether this can possibly be associated 
with poor clinical outcomes and comorbidities. The Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints (ECLIPSE) substudy tested the hypothesis that COPD 
is associated with increased ectopic fat accumulation and that this would be associated with 
COPD-related outcomes and comorbidities.
Methods: Computed tomography (CT) images of the thorax obtained in ECLIPSE were used to 
quantify ectopic fat accumulation at L2–L3 (eg, cross-sectional area [CSA] of visceral adipose 
tissue [VAT] and muscle tissue [MT] attenuation, a reflection of muscle fat infiltration) and 
CSA of MT. A dose–response relationship between CSA of VAT, MT attenuation and CSA 
of MT and COPD-related outcomes (6-minute walking distance [6MWD], exacerbation rate, 
quality of life, and forced expiratory volume in 1 second [FEV
1
] decline) was addressed with 
the Cochran–Armitage trend test. Regression models were used to investigate possible relation-
ships between CT body composition indices and comorbidities.
Results: From the entire ECLIPSE cohort, we identified 585 subjects with valid CT images at 
L2–L3 to assess body composition. CSA of VAT was increased (P,0.0001) and MT attenua-
tion was reduced (indicating more muscle fat accumulation) in patients with COPD (P,0.002). 
Pro gressively increasing CSA of VAT was not associated with adverse clinical outcomes. The 
probability of exhibiting low 6MWD and accelerated FEV
1
 decline increased with progres-
sively decreasing MT attenuation and CSA of MT. In COPD, the probability of having diabetes 
(P=0.024) and gastroesophageal reflux (P=0.0048) at baseline increased in parallel with VAT 
accumulation, while the predicted MT attenuation increased the probability of cardiovascular 
comorbidities (P=0.042). Body composition parameters did not correlate with coronary artery 
scores or with survival.
Conclusion: Ectopic fat accumulation is increased in COPD, and this was associated with 
relevant clinical outcomes and comorbidities.
Keywords: metabolic syndrome, obesity, abdominal adiposity, muscle
Introduction
Obesity is becoming a major health issue in patients with COPD, as it is in the gen-
eral population. Several studies have reported an increased proportion of patients 
with COPD who are either overweight or obese.1–4 Considering the well-established 
link between obesity and hypertension, type 2 diabetes, cancer and cardiovascular 
diseases (CVDs)5 and the fact that COPD is an independent risk factor for CVDs,6 
this increased prevalence of obesity in COPD is a source of concern. Consistent with 
these observations, all-cause mortality and cardiovascular mortality are also increased 
in patients with COPD.7 Depending on COPD severity, CVDs are the primary cause 
of mortality in 20%–27% of patients with COPD.8,9
Correspondence: François Maltais
Centre de Pneumologie, Institut 
universitaire de cardiologie et de 
pneumologie de Québec, 2725 
Chemin sainte-Foy, Québec, QC, 
Canada g1V 4g5
Fax +1 418 656 4762
email francois.maltais@fmed.ulaval.ca 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2017
Volume: 12
Running head verso: Martin et al
Running head recto: Adiposity and COPD
DOI: http://dx.doi.org/10.2147/COPD.S124750
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
452
Martin et al
One important issue to consider is that body mass index 
(BMI) is only a crude index of body composition while not 
allowing the quantification of ectopic fat accumulation. 
Rather than body size, body shape may be important to 
consider in the interpretation of the relationship between 
obesity and COPD. For instance, it is very well documented 
that the adverse metabolic and cardiovascular consequences 
of obesity are largely explained by the presence of unwanted 
adipose tissue (AT) accumulation in the abdomen and in 
normally lean tissues such as the liver, the heart and the 
skeletal muscles (collectively called ectopic fat tissue 
accumulation).10 Individuals with a selective accumulation of 
ectopic fat are at increased risk of developing features of the 
metabolic syndrome, diabetes, an atherogenic dyslipidemia, 
or CVDs compared to those who preferentially accumulate 
lipids in subcutaneous “healthy” AT.10
We took advantage of the Evaluation of COPD Longitudi-
nally to Identify Predictive Surrogate Endpoints (ECLIPSE) 
cohort with a 3-year follow-up to address the following 
questions: 1) Is COPD associated with increased ectopic 
fat accumulation within the abdomen and in the muscles? 
2) Does ectopic fat accumulation modify the expression 
of COPD in being associated with reduced functional and 
health status, as well as with forced expiratory volume in 
1 second (FEV
1
) rate of decline, exacerbations, mortality and 
cardiovascular comorbidities? Our overarching hypothesis 
was that COPD would be associated with increased ectopic 
fat accumulation compared to controls with normal lung 
function and that this would be associated with adverse 
clinical outcomes.
Methods
study design and patients
ECLIPSE (ClinicalTrials.gov, NCT00292552) was a mul-
ticenter, observational and longitudinal study to identify 
surrogate markers of COPD progression.11 It enrolled 2,164 
current or ex-smokers ($10 pack-years) with Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) stages 
2–4, 337 smokers with normal lung function and 245 never-
smokers.12 All ECLIPSE participants underwent a low-dose 
volumetric computed tomography (CT) scan of the chest at 
baseline. In a subset of them that constitutes the population 
for the current report, a valid CT scan slice at L2–L3 could 
be identified, allowing to assess body composition from 
which fat and muscle densities, a reflection of tissue fatty 
infiltration, could be accurately quantified.13
Patients’ characteristics (age, race, sex, smoking history), 
chest CT scan, pulmonary function tests, St Georges’ Respi-
ratory Questionnaire (SGRQ) score and 6-minute walking 
distance (6MWD) were obtained at baseline and yearly for the 
3-year study duration as previously reported.11,14,15 Standard-
ized questionnaires were used to record comorbidity at base-
line. COPD exacerbations and mortality were also recorded. 
All patients provided written informed consent, and the study 
was approved by the ethics committees of the participating 
centers. The ECLIPSE steering and scientific committees 
approved the protocol for this substudy (Table S1).
Body composition and coronary artery 
calcification assessment
All ECLIPSE participants underwent a low-dose volumetric 
CT scan of the chest at baseline with the following protocol: 
120-kV peak, 40 mA, and 1.00- or 1.25-mm slice thickness, 
at full inspiration. For the purpose of this ECLIPSE sub-
study, we analyzed all subjects with a thoracic CT scan that 
contained images at L2–L3 intervertebral space. Ectopic fat 
accumulation was quantified by measuring cross-sectional 
area (CSA) of visceral adipose tissue (VAT) and muscle 
tissue (MT) attenuation, a reflection of muscle fat infiltration. 
Subcutaneous adipose tissue (SCAT) and CSAs of MT were 
also assessed. Measures of fat and MT (psoas, paraspinal 
and abdominal wall muscles) CSA and attenuation were 
performed by the same investigator (MM) using the body 
composition analysis platform of the Institut universitaire 
de cardiologie et de pneumologie de Québec and a special-
ized image analysis software (sliceOmatic; TomoVision, 
Montreal, QC, Canada) according to standardized techniques 
(Figure 1).13 CSAs of AT and MT were measured using an 
attenuation range of −190 to −30 Hounsfield units (HUs) 
and −29 to 130 HUs, respectively. The mean attenuation 
value in HU of each structure was generated. To avoid 
subjectivity in the separation between SCAT and VAT, these 
two fat tissues were separated from each other midway in the 
thickness of abdominal wall muscles. Subjects for whom a 
tissue surface area .1 cm2 fell outside the field of view of the 
scope were excluded from further analysis. A random selec-
tion of 10% of all segmented images was redone by the same 
evaluator to assess for intraobserver variation. Interobserver 
variation was evaluated on a random sample of 10% of the 
segmented images that were also analyzed by a second imag-
ing expert. We also took advantage of the thoracic CT scan to 
quantify coronary artery calcification, a surrogate of coronary 
artery disease, using standardized techniques.16
statistical analyses
Characteristics were compared between patients with 
COPD and controls (smokers with normal lung function 
and never-smokers), using Student’s t-test statistics for 
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continuous variables and chi-square statistics for discrete 
variables. Coronary artery calcification scores were analyzed 
on a log
10
 scale because of their lognormal distribution. 
Patients with COPD were further classified according to 
the GOLD spirometric classification system.17 The overall 
test–retest reproducibility of each body composition param-
eter was assessed by calculating a Pearson’s correlation 
coefficient between evaluation 1 and evaluation 2 for each 
CT body composition parameter. Test–retest reliability was 
evaluated using intraclass correlation coefficient (ICC) as 
it reflects both systematic and random differences in test 
measures.18 An ICC .0.75 was judged to be excellent.19 
CT body composition variables were compared between 
patients with COPD and controls, and also across GOLD 
spirometric grades, using a multivariate analysis of covari-
ance (MANCOVA) model, with age, sex, BMI and smoking 
status included as covariates. When a significant effect of 
groups or subgroups were identified, univariate analysis of 
covariance (ANCOVA) models were adjusted to investigate 
which body composition variables were different, and least 
significant difference-protected multiple comparisons were 
performed to differentiate the subgroups.
The association between body composition parameters 
with clinical outcomes of interest (6MWD, exacerbation 
rate, quality of life, FEV
1
 decline) was addressed using the 
Cochran–Armitage trend test to determine a dose–response 
relationship between CSA of VAT, mean MT attenuation, 
CSA of MT and each of the clinical outcomes. For this 
analysis, body composition parameters (explanatory vari-
ables) were expressed in four equal groups determined by 
their quartiles. In this analysis, quartile 1 was considered 
as the reference value, while quartiles 2, 3 and 4 indi-
cated progressive increase in ectopic fat accumulation or 
decrease in CSA of MT. Each patient-reported outcome 
was expressed as dichotomous variables using specific 
cut-points: 350 m for the 6MWD,20 more than or equal to 
Figure 1 Body composition analysis and differences in fat distribution.
Notes: examples of a CT slice at l2–l3 before (A) and after segmentation (B). an example is also provided for two patients with COPD with same BMI and similar waist 
circumference but marked difference in body composition, with one patient (C) having more VaT (shown in red) than the other patient (D). after segmentation, sCaT was 
identified in green, VAT in red and MT in pink. CSAs of tissues (cm2) were computed on the segmented structures using an attenuation range of −190 to –30 hUs for aT 
and −29 to 130 HUs for MT. The mean attenuation value in HU of each structure was also quantified.
Abbreviations: CT, computed tomography; BMI, body mass index; sCaT, subcutaneous adipose tissue; VaT, visceral adipose tissue; MT, muscle tissue; Csa, cross-
sectional area; HU, Hounsfield unit; AT, adipose tissue.
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two exacerbations per year,17 SGRQ score .2517 and FEV
1
 
decline .40 mL/year.21 The impact of body composition on 
comorbidities was assessed by logistic regression models, 
while its relationship with survival was studied using a Cox 
proportional hazards regression model. All analyses were 
controlled for age, sex, BMI, smoking status and FEV
1
. 
P-values ,0.05 were considered statistically significant. 
Data analyses were performed using SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA).
Results
We identified 585 patients (511 patients with COPD and 
74 controls) for whom a CT slice at L2–L3 could be analyzed 
for body composition assessment. Patients’ characteristics 
are outlined in Table 1. Patients with COPD and controls had 
similar BMI but important differences were otherwise noted: 
patients with COPD were older, had a higher proportion of 
men and were current/former smokers compared to controls. 
They also exhibited higher SGRQ scores (worse health-
related quality of life), greater prevalence of cardiovascular 
comorbidities (angina, heart attack, myocardial infarction, 
stroke and heart failure), hypertension and greater coronary 
artery calcification score than controls. During the 3-year 
follow-up, 50 deaths were recorded (49 patients with COPD 
and one control), resulting in lower mean survival days in 
patients with COPD. A total of 1,661 moderate-to-severe 
exacerbations were reported in patients with COPD, with 
a mean exacerbation rate of 1.28±0.06/year/patient (range: 
0–9/year/patient).
The Pearson’s coefficient and ICC for each body com-
position parameter are reported in Table 2 and show an 
excellent intra- and inter-observer reproducibility of our 
body composition measurements.
CT body composition data adjusted for age, sex, smoker 
status and BMI are presented in Figure 2. For a similar BMI 
(Figure 2A), patients with COPD exhibited higher CSA of 
VAT (Figure 2B), lower MT attenuation (Figure 2C) and a 
tendency to have lower CSA of MT (Figure 2D) than controls. 
CSA of SCAT could be quantified in 384 subjects (327 COPD 
subjects and 57 controls) in whom the abdomen external wall 
Table 1 Baseline characteristics by group
Variables COPD (n=511) Controls (n=74) P-value
age (years) 63.8±6.9 56.8±10.0 ,0.0001
BMI (kg/m2) 24.4±5.0 25.3±4.3 0.1761
sex
Male, n (%) 314 (61) 30 (41) 0.0007
Female, n (%) 197 (39) 44 (59)
smoking status
Current smokers, n (%) 201 (39) 20 (27) ,0.0001
Former smokers, n (%) 310 (61) 17 (23)
never-smokers, n (%) 0 (0) 37 (50)
Pack/year 48.7±1.1 14.9±4.4 ,0.0001
Pulmonary function
FeV1 (% predicted value) 40.7±15.3 108.3±13.2 ,0.0001
FVC (l) 2.71±0.9 4.07±0.9 ,0.0001
FeV1/FVC 0.41±0.01 0.79±0.01 ,0.0001
FeV1 decline (l/year) 0.052±0.023 na na
Clinical variables
sgrQ total score 48.4±17.2 9.5±9.7 ,0.0001
6MWD (m) 366.3±5.7 na na
exacerbation number (number/years) 1.3±0.1 0 (0) ,0.0001
Mortality, n (%) 49 (9.5) 1 (1.3) 0.02
Mean survival (days) 1,016±6 1,060±5 ,0.01
Comorbidities
Cardiovascular†, n (%) 255 (50) 1 (1) 0.0078
hypertension, n (%) 175 (34) 9 (12) 0.0001
CaC score, agatston units 540±45 251±120 0.0005
Diabetes, n (%) 31 (6) 1 (1) 0.1068
Reflux/heartburn, n (%) 110 (22) 15 (20) 0.8802
Notes: Data shown as mean ± se or n (%). †Includes angina, heart attack, myocardial infarction, stroke and heart failure.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; na, not applicable; sgrQ, st george’s respiratory 
Questionnaire; 6MWD, 6-minute walking distance; CAC, coronary artery calcification; SE, standard error.
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body composition parameters were particularly notable in 
patients with GOLD 4 COPD. Interestingly, progressively 
decreasing MT attenuation and CSA of MT were associated 
with increased probability of experiencing worse functional 
status and FEV
1
 decline and prevalence of CVDs, while 
VAT accumulation was associated with the prevalence of 
diabetes and gastroesophageal reflux at study entry. Impor-
tantly, these associations remained after adjustment for age, 
sex, BMI, smoking status and FEV
1
.
We are not aware of previously published study on 
intra-abdominal muscle attenuation and CSA data in COPD. 
Similar to our findings involving the psoas, paraspinal and 
abdominal wall muscles, evidence of fat infiltration and 
atrophy of the quadriceps has been reported in COPD.23,24 
The same authors also reported inverse relationships between 
indices of quadriceps’ fat infiltration and walking capacity 
in COPD. In this context, it is interesting that lower intra-
abdominal MT density, a reflection of increased fatty content, 
and reduced muscle intra-abdominal CSAs were associated 
with increased probability of having a 6MWD ,350 m. 
It could be argued that the performance of the psoas and 
paraspinal muscles that are involved in walking was altered 
by a combination of fat infiltration and reduced area, together 
leading to impaired muscle contractility.24,25 Alternatively, 
intra-abdominal muscle fat infiltration and atrophy may sim-
ply be a reflection of a generalized process involving several 
muscle groups, including those of the lower limbs.
The mechanisms for ectopic fat accumulation in COPD 
were not investigated. These phenomena have been associ-
ated with insulin resistance,26 resulting from a combination of 
factors, including age, genetics, poor diet, smoking and lack 
of vigorous physical activity, to only name a few.10 Another 
potential contributor to ectopic fat accumulation in COPD 
that was not addressed in the present study included repeated 
use of systemic corticosteroid to treat COPD exacerbations.27 
We also did not have direct measurement of physical activity 
and dietary habits.7
Ectopic fat is metabolically active as evidenced by its 
production of a host of proinflammatory mediators, includ-
ing TNF-α, IL-6, leptin and adiponectin, whose effects 
may be seen not only locally within the AT but also at the 
systemic level. Considering systemic inflammation as a risk 
factor for CVDs and possibly for COPD progression,28,29 we 
speculated that ectopic fat accumulation would be associ-
ated with adverse clinical outcomes such as poor functional 
status and quality of life, increased exacerbation risk and 
faster FEV
1
 decline as well as with cardiovascular comor-
bidities. Although this interpretation is partly supported by 
fell inside the field of view. SCAT was greater in patients with 
COPD than in controls (Figure 2E). The same results are also 
presented according to the severity of airflow obstruction from 
GOLD stages 2 to 4. Patients with GOLD 3 and 4 COPDs had 
lower BMI than GOLD 2 patients, while GOLD 4 patients 
were characterized by larger CSAs of VAT and SCAT and 
less MT attenuation than the remaining groups.
The associations between body composition parameters 
and COPD-associated clinical outcomes are shown in 
Figure 3. Progressively increasing CSA of VAT was not 
associated with worsening in functional status (6MWD), 
exacerbation rate and FEV
1
 decline but it was associated 
with a reduced odds ratio of having SGRQ scores .25 
(indicating worse health status). In contrast, progressively 
decreasing MT attenuation and CSA of MT were associated 
with increased probability of exhibiting low 6MWD and 
accelerated FEV
1
 decline. In COPD, the probability of having 
diabetes (P=0.024) and gastroesophageal reflux (P=0.0048) 
at baseline increased in parallel with VAT accumulation, 
while MT attenuation predicted increased probability of 
cardiovascular comorbidities (P=0.042; Figure 4). Body 
composition parameters did not correlate with coronary artery 
scores or with survival.
Discussion
This ECLIPSE substudy reports increased ectopic AT accu-
mulation in a large group of patients with COPD compared 
to controls with normal lung function. Patients with COPD 
were characterized by increased CSA of VAT and evidence 
of muscle fat infiltration as assessed by CT as well as by an 
increased prevalence of cardiovascular comorbidities. Our 
study is concordant and extends existing knowledge that 
patients with COPD are associated with increased VAT 
accumulation compared to controls7,22 by reporting, for 
the first time, decreased MT attenuation (consistent with 
increased fat infiltration) in COPD and investigating the 
relationship between ectopic fat accumulation and COPD-
related outcomes and comorbidities. Alterations in CT 
Table 2 Internal validity and external validity of the CT image 
analysis
Variables Internal validity External validity
Pearson’s r Intraclass r Pearson’s r Intraclass r
VaT surface 1.00 1.00 1.00 1.00
MT surface 0.99 0.99 0.99 0.99
MT attenuation 1.00 1.00 0.95 0.95
sCaT 1.00 1.00 0.99 0.99
Abbreviations: CT, computed tomography; VaT, visceral adipose tissue; MT, 
muscle tissue; sCaT, subcutaneous adipose tissue.
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Figure 2 group mean values ± sD for BMI (A), Csa of VaT (B), MT attenuation (C), Csa of MT (D) and Csa of sCaT (E) in patients with COPD (gray bars) and in 
controls (black bars).
Note: Patients with COPD were further classified according to the GOLD spirometric classification system, with a greater score indicating worse airflow obstruction.
Abbreviations: BMI, body mass index; Csa, cross-sectional area; VaT, visceral adipose tissue; MT, muscle tissue; sCaT, subcutaneous adipose tissue; gOlD, global 
Initiative for Chronic Obstructive Lung Disease; HU, Hounsfield unit; SD, standard deviation.
our data, the reported association between ectopic fat accu-
mulation, clinical outcomes and comorbidities should not 
be viewed as implying causal relationships. Nevertheless, 
these associations point to the fact that ectopic fat accumu-
lation could be detrimental to cardiovascular and metabolic 
health in COPD.
Investigators from the COPDGene study reported a signifi-
cant association between the amount of VAT and the risk of 
having a history of a previous myocardial infarction in patients 
with COPD.30 In the present investigation, we found that CSA 
of VAT and muscle attenuation were, respectively, associated 
with increased prevalence of diabetes and cardiovascular 
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comorbidities at study entry. These results are consistent with 
the bulk of knowledge recognizing ectopic fat accumulation as 
a risk factor for cardiovascular and metabolic diseases.10 We did 
not find, however, an association between the extent of coro-
nary artery calcification and VAT in this cohort. This may be 
an indication that the mechanisms by which VAT contributes 
to CVD risk do not mainly involve a calcification process.
Our study has several strengths. It involves an appreciable 
number of patients with longitudinal follow-up, offering the 
possibility of studying the clinical consequences of ectopic 
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Abbreviations: CT, computed tomography; Csa, cross-sectional area; VaT, visceral adipose tissue; MT, muscle tissue; 6MWD, 6-minute walking distance; sgrQ, st 
george’s respiratory Questionnaire; FeV1, forced expiratory volume in 1 second; CI, confidence interval.
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fat accumulation. The international scope of the study also 
supports the generalizability of the data. Body composition 
analysis was performed rigorously, according to standardized 
and recommended procedures.13 There are however potential 
limitations that need to be considered in interpreting the data. 
Despite the relatively large study sample and the 3-year 
follow-up, the number of deaths (n=50) was likely too small 
to secure the notion of a possible relationship between ectopic 
fat accumulation and survival in COPD. Because ECLIPSE 
CT scans were not performed purposely to determine body 
composition, the analysis had to be restricted to those par-
ticipants with abdominal CT images, which would be valid 
for segmentation of AT and muscle area and densities. We 
do not believe, however, that these issues compromise the 
validity of our findings because baseline characteristics of 
patients involved in this substudy were similar to those of 
the entire ECLIPSE cohort.12
ECLIPSE did not mandate to match control subjects 
with patients with COPD. As such, important differences in 
age, sex distribution and smoking status were seen between 
the two groups. This issue was addressed by controlling for 
baseline differences for these variables in all analyses. In 
addition, physical activity levels were not assessed, making 
it difficult to comment on the potential impact of sedentary 
behaviors on the body composition differences observed in 
COPD in this cohort. Although ECLIPSE was a considerable 
undertaking, it remains that 3 years of follow-up was likely 
too short to highlight the clinical impact of body composi-
tion abnormalities, particularly in this cohort of patients with 
advanced COPD. Finally, some important well-established 
cardiovascular risk factors such as lipid and glycemic profile 
were not assessed. In this regard, it could be argued that 
these traditional risk factors could at least partly capture the 
elevated cardiovascular risk in COPD.
Conclusion
Our study adds to the existing knowledge by confirming the 
presence of increased ectopic fat accumulation in COPD. 
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Figure 4 Logistic regression models indicating significant correlations between CT body composition parameters and the proportion of comorbidities for diabetes (A), 
gastroesophageal reflux (B), and CVD (C) at baseline.
Note: Continuous lines were drawn from the mean regression coefficients with the dashed lines representing the 95% CI of the relationships.
Abbreviations: CT, computed tomography; CI, confidence interval; VAT, visceral adipose tissue; CSA, cross-sectional area; CVD, cardiovascular disease; MT, muscle tissue; 
HU, Hounsfield unit.
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
459
adiposity and COPD
In this patient population, body composition abnormalities in 
the form of increased CSA of VAT and fat infiltration of intra-
abdominal muscle and reduced CSA of intra-abdominal 
muscle were associated with cardiovascular comorbidities, 
diabetes and gastroesophageal reflux as well as with relevant 
clinical outcomes such as walking capacity and FEV
1
 decline. 
As successfully accomplished in other patient populations, 
we submit that assessing the level of ectopic fat accumula-
tion is relevant in COPD. In addition, we suggest that we 
should also consider the development of lifestyle modifi-
cation programs focusing on both nutritional quality and 
physical activity/exercise with the objective of improving 
AT distribution/ectopic fat in patients with COPD.
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